文献速递瓣膜外科

生物瓣瓣环断裂:多中心研究的技术见解

Bioprosthetic valve fracture: Technical insights from a multicenter study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-01-31

本研究在21个中心对75例外科生物瓣衰败患者行瓣中瓣经导管主动脉瓣置换(VIV TAVR)联合生物瓣瓣环断裂(BVF)。结果显示BVF安全,最终平均跨瓣压差为9.2±6.3 mmHg;在VIV TAVR后行BVF并使用较大球囊是较低最终压差的独立预测因素。

要点

  • BVF在VIV TAVR后实施较先实施BVF显著降低最终平均跨瓣压差。
  • 使用较大BVF球囊是较低最终平均压差的独立预测因素。
  • BVF未发生主动脉根部破裂、冠状动脉阻塞或新起搏器植入。

核心结论

  • BVF可安全实施并降低VIV TAVR后的残余跨瓣压差。
  • 在VIV TAVR后行BVF并使用较大球囊可获得最佳血流动力学结果。

研究设计与样本

  • 多中心研究,共纳入75例在21个中心接受BVF的患者。
  • 采用分层多元线性回归分析识别与较低最终跨瓣压差相关的变量。

主要发现

  • 外科瓣中位真内径为18.5 mm(四分位距17.0-20.5 mm)。
  • 使用球囊扩张式(n=43)或自膨胀式(n=32)经导管心脏瓣膜,中位尺寸23 mm(四分位距23-23 mm)。
  • 无主动脉根部破裂、冠状动脉阻塞或新起搏器植入;院内或30天死亡率为2.6%(2/75)。
  • 最终平均跨瓣压差为9.2±6.3 mmHg;VIV TAVR后行BVF组为8.1±4.8 mmHg,先BVF组为16.9±10.1 mmHg(P<.001)。
  • 调整BVF时机、瓣膜尺寸/类型、外科瓣失败模式、真内径、基线压差和BVF球囊尺寸后,VIV TAVR后行BVF(P<.001)和使用较大BVF球囊(P=.038)是较低最终平均压差的独立预测因素。

临床怎么用

  • 在VIV TAVR后实施BVF可能有助于降低残余跨瓣压差。
  • 选择较大BVF球囊可能改善最终血流动力学结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Valve-in-valve transcatheter aortic valve replacement (VIV TAVR) can result in high residual gradients that are associated with increased mortality. Bioprosthetic valve fracture (BVF) has been shown to improve residual gradients following VIV TAVR; however, factors influencing the results of BVF have not been studied. METHODS: BVF was performed in 75 patients at 21 centers. Hierarchical multiple linear regression was performed to identify variables that were associated with lower final transvalvular gradient. RESULTS: Surgical valves with a median true internal diameter of 18.5 mm (interquartile range, 17.0-20.5 mm) were treated with VIV TAVR in conjunction with BVF using balloon-expandable (n = 43) or self-expanding (n = 32) transcatheter heart valves with a median size of 23 mm (interquartile range, 23-23 mm). There were no aortic root disruptions, coronary occlusions, or new pacemakers; in-hospital or 30-day mortality was 2.6% (2 out of 75). Final mean transvalvular gradient was 9.2 ± 6.3 mm Hg, but was significantly lower when BVF was performed after VIV TAVR compared with BVF first (8.1 ± 4.8 mm Hg vs 16.9 ± 10.1 mm Hg; P < .001). After adjusting for timing of BVF (ie, before or after VIV TAVR), transcatheter heart valve size/type, surgical valve mode of failure, true internal diameter, and baseline gradient and BVF balloon size, performing BVF after VIV TAVR (P < .001) and using a larger BVF balloon (P = .038) were the only independent predictors of lower final mean gradient. CONCLUSIONS: BVF can be performed safely and results in reduced residual transvalvular gradients. Performing BVF after VIV TAVR and using larger balloon appears to achieve the best hemodynamic results.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Allen KB, Chhatriwalla AK, Saxon JT, et al. Bioprosthetic valve fracture: Technical insights from a multicenter study. J Thorac Cardiovasc Surg. 2019. PMID: 30857820. doi:10.1016/j.jtcvs.2019.01.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。